A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Maalox Advanced Maximum Strength and One A Day Maximum on Pharmacokinetics of GSK1349572 in Healthy Adult Subjects.

Trial Profile

A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Maalox Advanced Maximum Strength and One A Day Maximum on Pharmacokinetics of GSK1349572 in Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs Aluminium hydroxide/magnesium hydroxide; Dolutegravir; Vitamins
  • Indications Gastrointestinal disorders; HIV infections; HIV-1 infections; Hyperchlorhydria
  • Focus Pharmacokinetics
  • Acronyms DDI
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Sep 2009 Results have been reported at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 19 Mar 2009 Actual patient number (16) added as reported by ClinicalTrials.gov.
    • 19 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top